Carbocain (Mepivacaine): Uses, Dosage & Side Effects

What Is Carbocain and What Is It Used For?

Carbocain contains the active substance mepivacaine hydrochloride, a local anesthetic that reversibly blocks the transmission of nerve impulses along nerve fibers. When injected near a nerve or into the tissue surrounding a surgical site, mepivacaine prevents sodium ions from flowing through the nerve cell membrane, which is essential for generating and conducting electrical signals. This results in a temporary loss of sensation, including pain, in the area served by the blocked nerves.

Mepivacaine was first synthesized in 1956 by A.F. Ekenstam and colleagues at Bofors in Sweden, and was introduced into clinical practice in the early 1960s. It quickly became one of the most popular local anesthetics in dentistry and regional anesthesia due to its rapid onset of action, predictable duration, and relatively low toxicity profile. Today, mepivacaine remains one of the most widely used local anesthetics globally, recognized by the World Health Organization and endorsed by major anesthesiology societies including the European Society of Regional Anaesthesia and Pain Therapy (ESRA) and the American Society of Regional Anesthesia and Pain Medicine (ASRA).

Carbocain is used for a wide range of clinical indications. In dentistry, it is the preferred agent for many procedures because it provides effective anesthesia without the need for a vasoconstrictor in many situations. For surgical procedures, it can be used for local infiltration anesthesia (numbing a small area of tissue), peripheral nerve blocks (blocking specific nerves to numb larger regions), plexus blocks (such as brachial plexus blocks for upper extremity surgery), and epidural anesthesia (numbing the lower body for surgical and obstetric procedures). The versatility of mepivacaine makes it suitable for both ambulatory day-case surgery and more complex inpatient procedures.

A distinctive pharmacological property of mepivacaine is its relatively weak vasodilatory effect compared to other local anesthetics such as lidocaine. This means that mepivacaine is absorbed more slowly from the injection site without the need for a vasoconstrictor additive (such as epinephrine), which translates to a longer duration of anesthesia in its plain formulation. This property makes Carbocain particularly valuable for patients in whom epinephrine is contraindicated, such as those with certain cardiovascular conditions, uncontrolled hypertension, or those taking monoamine oxidase inhibitors (MAOIs).

Carbocain is available as a solution for injection in concentrations of 10 mg/ml (1%) and 20 mg/ml (2%). The 1% solution is typically used for infiltration anesthesia and minor nerve blocks, while the 2% solution is used for major nerve blocks and epidural anesthesia where a denser block is required. Both concentrations are provided in 20 ml glass vials. The solution is preservative-free and should be used immediately after opening. It is a clear, colorless solution that should not be used if it appears discolored or contains particulate matter.

What Should You Know Before Receiving Carbocain?

Contraindications

There are specific medical situations in which Carbocain must not be used. Understanding these contraindications is essential for your safety. Your healthcare provider will screen for these conditions before administering the medication. You should not receive Carbocain if:

• Known allergy to mepivacaine: If you have a documented allergy or hypersensitivity to mepivacaine hydrochloride or any of the other ingredients in the formulation (sodium chloride, sodium hydroxide, hydrochloric acid, water for injections).
• Allergy to other amide-type local anesthetics: If you are allergic to other local anesthetics in the same chemical class, such as bupivacaine, lidocaine, ropivacaine, or prilocaine, you should not receive Carbocain, as cross-reactivity may occur.
• Severe shock with epidural administration: Carbocain must not be used for epidural anesthesia in patients who are in severe cardiovascular shock (e.g., from massive hemorrhage, severe cardiac failure, or major fluid losses), as the sympathetic blockade produced by epidural anesthesia can worsen hemodynamic instability.

Warnings and Precautions

Your healthcare provider should exercise particular caution and closely monitor you during and after the administration of Carbocain if any of the following conditions apply:

• Elderly patients or those in poor general condition: These patients may be more susceptible to the systemic effects of local anesthetics due to altered drug distribution and reduced hepatic clearance. Lower doses are typically required.
• Heart disease: Patients with structural heart disease, congestive heart failure, or ischemic heart disease may be at increased risk for cardiovascular complications. Mepivacaine, like all local anesthetics, can affect cardiac conduction and contractility at elevated plasma levels.
• AV block (grade II or III): Mepivacaine can further impair atrioventricular conduction. Patients with pre-existing second- or third-degree heart block are at particular risk and generally should not receive amide-type local anesthetics.
• Treatment with antiarrhythmic drugs: Concurrent use of Class I antiarrhythmic agents (such as mexiletine, tocainide, or flecainide) can produce additive cardiac depressant effects when combined with mepivacaine, as these drugs share similar mechanisms of action on sodium channels.
• Severe liver disease: Mepivacaine is metabolized primarily in the liver by microsomal enzymes (predominantly CYP1A2 and CYP3A4). Severe hepatic impairment significantly reduces the clearance of mepivacaine, increasing the risk of systemic toxicity. Dose reduction and careful monitoring are essential.
• Severe kidney impairment: While mepivacaine metabolites are excreted renally, severe kidney dysfunction may lead to accumulation of active metabolites, particularly with repeated dosing.
• Acute porphyria: Mepivacaine is considered potentially porphyrinogenic and should be avoided in patients with acute intermittent porphyria, variegate porphyria, or hereditary coproporphyria, as it may trigger an acute porphyric crisis.

Use in Children

Carbocain should not be given to neonates and infants under 6 weeks of age. The neonatal liver has significantly reduced capacity to metabolize amide-type local anesthetics because the cytochrome P450 enzyme systems are immature at birth. This results in prolonged plasma half-lives and an increased risk of systemic toxicity.

For children older than 6 weeks, Carbocain can be used, but clinical data in very young children are limited. The physician must calculate the appropriate dose based on the child's body weight and must exercise particular caution. Reduced concentrations and volumes should be used, and the total dose should not exceed the recommended maximum on a mg/kg basis. For children aged 6 weeks to 12 years, the physician will determine the appropriate dose based on patient weight, the area to be anesthetized, and the specific technique employed.

Pregnancy and Breastfeeding

There are no known risks associated with the use of Carbocain during pregnancy for routine local anesthetic procedures. Mepivacaine has been used safely for dental anesthesia and minor surgical procedures during pregnancy for decades, and regulatory agencies have not identified specific teratogenic risks associated with its use at standard doses.

However, Carbocain is not recommended for paracervical block during labor, as this technique has been associated with fetal bradycardia. Additionally, mepivacaine is not the preferred agent for epidural anesthesia during cesarean section; other local anesthetics such as bupivacaine or ropivacaine are typically chosen for this indication due to their more favorable pharmacokinetic profiles in obstetric patients.

Mepivacaine passes into breast milk in small amounts, but at the doses used for local anesthetic procedures, it is unlikely to affect a nursing infant. The American Academy of Pediatrics considers local anesthetics generally compatible with breastfeeding. Nevertheless, if you are breastfeeding, inform your healthcare provider so they can provide appropriate guidance.

Driving and Operating Machinery

Depending on the dose administered and the specific technique used, Carbocain may temporarily affect your ability to move, coordinate, and concentrate. The effects on motor function and alertness depend on the nerves that are blocked: epidural or major nerve block anesthesia will significantly impair mobility and sensation in the affected areas until the anesthetic effect wears off. Even after infiltration anesthesia, you should assess your own ability to drive or operate machinery before doing so. Your healthcare provider will advise you on when it is safe to resume these activities.

How Does Carbocain Interact with Other Drugs?

Although Carbocain is typically administered as a single dose in a clinical setting, it is important for your healthcare provider to know about all medications you are taking. Several drug interactions can increase the risk of systemic toxicity or alter the effectiveness of mepivacaine. The following interactions have been documented in clinical practice and pharmacological studies:

Major Interactions

Minor Interactions

It is also important to note that the injection solution should not be stored in contact with metals, such as needles or syringes with metallic components, for prolonged periods. Metal ions can leach into the solution, potentially causing tissue irritation at the injection site. Additionally, alkalinization of the solution should be avoided, as mepivacaine has poor solubility at pH values above 6.5, which may result in precipitation.

What Is the Correct Dosage of Carbocain?

Carbocain is always administered by a qualified healthcare professional. The dose is individualized based on the type of anesthesia required, the area and extent of the surgical field, the vascularity of the tissues, the number of neuronal segments to be blocked, the depth and duration of anesthesia needed, and the patient's physical condition, age, and body weight. Your healthcare provider will always use the lowest dose that provides adequate anesthesia.

Adults

Children

Carbocain should not be given to neonates and infants under 6 weeks of age. For children between 6 weeks and 12 years of age, the physician calculates the appropriate dose based on the patient's body weight. The dose per kilogram is generally lower than for adults, and the total dose must be carefully calculated to avoid systemic toxicity. As a general guideline, the maximum dose for children should not exceed 5-6 mg/kg body weight. Only low concentrations (1% or less) should be used, and the volume should be adjusted to the minimum required for adequate anesthesia.

Elderly

Elderly patients are more susceptible to the effects of local anesthetics due to age-related changes in physiology, including reduced hepatic blood flow, decreased liver enzyme activity, reduced cardiac output, and altered body composition. Dose reduction is recommended, and the lowest effective dose should always be used. The onset of anesthesia may be faster in elderly patients due to reduced nerve fiber density, while the duration may be prolonged due to slower clearance. Close monitoring of cardiovascular and neurological status is essential during and after administration.

Overdose

Overdose with local anesthetics such as mepivacaine can occur due to inadvertent intravascular injection (injection into a blood vessel), excessive dosing, or rapid absorption from the injection site. Toxic reactions typically manifest within 15-60 minutes after injection, although accidental intravascular injection can produce symptoms within seconds to minutes.

The progression of systemic toxicity typically follows a predictable pattern. Initial symptoms involve the central nervous system (CNS) and include a feeling of inebriation, numbness around the mouth and tongue, visual disturbances (blurred or double vision), tinnitus (ringing in the ears), and heightened sensitivity to sounds. As plasma levels increase, more severe manifestations can develop, including difficulty speaking clearly, muscle twitching and tremors, and eventually generalized seizures and loss of consciousness.

Cardiovascular toxicity may accompany or follow CNS symptoms and includes hypotension (low blood pressure), bradycardia (slow heart rate), cardiac arrhythmias, and in severe cases, cardiac arrest and respiratory arrest. For this reason, resuscitation equipment and emergency medications—including intravenous lipid emulsion (Intralipid), which is the specific antidote for local anesthetic systemic toxicity (LAST)—must always be immediately available when Carbocain is used.

What Are the Side Effects of Carbocain?

Like all medications, Carbocain can cause side effects, although not everybody experiences them. Many side effects of local anesthetics are dose-dependent and related to the plasma concentration of the drug. Your healthcare provider will monitor you closely during and after the administration of Carbocain to detect and manage any adverse effects promptly.

It is important to distinguish between side effects caused by the local anesthetic itself and effects that result from the anesthetic technique. For example, hypotension during epidural anesthesia is primarily a consequence of the sympathetic nerve blockade rather than a direct drug effect. Similarly, temporary nerve damage can result from needle trauma or compression rather than the pharmacological action of mepivacaine. Your healthcare provider will assess and differentiate between these possibilities if any complications arise.

Allergic reactions to amide-type local anesthetics such as mepivacaine are extremely rare, estimated at less than 1% of all adverse reactions. Most reported "allergies" to local anesthetics are actually vasovagal reactions (fainting due to anxiety), reactions to epinephrine additives, or toxic reactions from excessive dosing. True IgE-mediated allergic reactions to amide local anesthetics are documented but occur very infrequently. If you have a history of suspected allergy to local anesthetics, your healthcare provider may arrange for allergy testing before the procedure.

How Should Carbocain Be Stored?

Carbocain should be stored at a temperature not exceeding 25°C (77°F) and must not be frozen. Freezing can alter the physical and chemical properties of the solution, potentially affecting its sterility, pH, and efficacy. The medication should be kept out of the sight and reach of children at all times.

As Carbocain injection solution does not contain preservatives, it should be used immediately after the vial is opened. Any unused solution remaining in the vial after opening must be discarded and should not be stored for later use. This is to prevent bacterial contamination that could lead to serious infections if a contaminated solution were injected. Healthcare facilities follow strict protocols for the handling and disposal of opened vials.

Do not use Carbocain after the expiration date printed on the vial label and the outer carton. The expiration date refers to the last day of the stated month. Do not use the solution if it appears discolored, cloudy, or contains visible particles. Discoloration or particulate matter may indicate chemical degradation or contamination.

Unused or expired medications should be disposed of according to local pharmaceutical waste regulations. Do not dispose of medications in household waste or wastewater. Healthcare facilities have dedicated pharmaceutical waste disposal procedures. If you are a patient given a vial to take home (which is uncommon for this injectable medication), ask your pharmacist about the proper disposal method in your area.

What Does Carbocain Contain?

The active substance in Carbocain is mepivacaine hydrochloride. Each milliliter of the 10 mg/ml solution contains 10 mg of mepivacaine hydrochloride, and each milliliter of the 20 mg/ml solution contains 20 mg of mepivacaine hydrochloride.

The other ingredients (excipients) in Carbocain are:

• Sodium chloride: Added to make the solution isotonic (having the same salt concentration as body fluids), which minimizes tissue irritation upon injection. The 10 mg/ml solution contains approximately 63 mg of sodium per 20 ml vial (equivalent to 3.15% of the maximum recommended daily sodium intake for adults). The 20 mg/ml solution contains approximately 55 mg of sodium per 20 ml vial (2.75% of the recommended daily intake).
• Sodium hydroxide and/or hydrochloric acid: Used to adjust the pH of the solution to an appropriate range for injection (approximately pH 4.5-6.5). This pH range maintains the stability and solubility of mepivacaine hydrochloride while minimizing tissue irritation.
• Water for injections: The pharmaceutical-grade solvent used to dissolve the active and inactive ingredients.

Carbocain is supplied as a clear, colorless solution for injection in glass vials. Each vial contains 20 ml of solution, and each package contains 5 vials. The glass vials are designed to maintain the sterility and chemical stability of the solution until the expiration date when stored under the recommended conditions.

Carbocain does not contain preservatives, antimicrobial agents, heavy metals, or latex components. This is particularly relevant for patients with latex allergies or sensitivities to commonly used preservatives such as methylparaben. The absence of preservatives means that the solution is intended for single use only.